JNJ
StockJohnson & Johnson
Healthcare • NYSE
$234.20
Market Cap
$563.77B
Volume
8.44M
P/E Ratio
27.14
EPS
N/A
RSI (14)
55.0
52W Range
$149.04 - $251.71
Price Chart
Fundamental Analysis
Valuation
P/E Ratio
27.14
Forward P/E
18.42
PEG Ratio
3.06
Price/Book
6.94
Profitability
EPS
$N/A
Profit Margin
21.8%
Gross Margin
68.0%
ROE
26.4%
Financial Health
Market Cap
$563.77B
Debt/Equity
67.73
Current Ratio
1.02
Quick Ratio
0.69
Growth
Revenue Growth
9.9%
Earnings Growth
-52.9%
Dividend Yield
N/A
Beta
0.26
Technical Analysis
Momentum
RSI (14)
Neutral54.99
MACD
Bullish1.9291
Signal: 1.2559
Histogram: 0.6732
Stochastic %K
64.35
Williams %R
-35.65
Trend
SMA 20
Above$231.77
↑ 2.43
SMA 50
Above$230.63
↑ 3.57
SMA 200
Above$215.48
↑ 18.72
EMA 12
$234.13
EMA 26
$232.20
Volatility
Bollinger Bands
Price Position: Upper Half (62%)
ATR (14)
$5.07
Volatility: 2.16%
Price
$234.20
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.